Pure Global

Comparison of HR011408 and NovoRapid® in Subjects With Diabetics - Trial NCT06375031

Access comprehensive clinical trial information for NCT06375031 through Pure Global AI's free database. This Phase 1 trial is sponsored by Jiangsu HengRui Medicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Diabetes. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06375031
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06375031
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Comparison of HR011408 and NovoRapid® in Subjects With Diabetics
Comparing Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Subjects With Diabetics- A Randomized, Double-Blind, Three-cycle Crossover Phase I Clinical Trial

Study Focus

Diabetes

HR011408 injection; HR011408 injection Placebo

Interventional

drug

Sponsor & Location

Jiangsu HengRui Medicine Co., Ltd.

Hefei, China

Timeline & Enrollment

Phase 1

Apr 01, 2024

Jul 15, 2024

30 participants

Primary Outcome

Area under the serum concentration-time curve of insulin aspart

Summary

The objective of the study is to compare the pharmacokinetics and pharmacodynamics between
 HR011408 and NovoRapid® in Subjects with Diabetics.

ICD-10 Classifications

Diabetes mellitus
Unspecified diabetes mellitus
Other specified diabetes mellitus
Unspecified diabetes mellitus without complications
Other specified diabetes mellitus without complications

Data Source

ClinicalTrials.gov

NCT06375031

Non-Device Trial